- Reliance Life Sciences has developed an RT-PCR kit.
- The kit ensures the diagnosis of Covid-19 infection in about two hours.
- The kit presents 98.7% sensitivity and 98.8% specificity.
THDNewsDesk, New Delhi: Reliance Life Sciences has developed an RT-PCR kit that ensures Covid-19 infection diagnosis in about two hours, as per the company sources on 2nd of September.
The RT-PCR test suggests a real-time reverse transcription-polymerase chain reaction. Presently, (RT-PCR) test for the qualitative detection of nucleic acid from SARS-CoV-2 takes up to 24 hours to provide a diagnosis.
The company sources said that the computational biologists at Reliance Life Sciences are a part of billionaire Mukesh Ambani owned Reliance Industries Ltd. It examined over 100 genomes of SARS-CoV-2 sequenced in India and created unique RT-PCR primers for developing quantitative-Real Time PCR (RT-PCR) kit for Covid-19 detection. RT-PCR kit is considered the gold standard for testing.
The sources further added that the kit developed by scientists at Reliance Life Sciences is named R-Green Kit (SARS COV2-real-time PCR). The equipment has been ICMR verified for determining adequate performance.
Though, ICMR’s verification process does not promote or repudiate the kit design. It does not accredit user-friendliness. The sources said the kit could detect the presence of E-gene, R-gene, RdRp gene ofSARS COV2 virus with Actin as an internal control.
According to ICMR results, the kit presents 98.7% sensitivity and 98.8% specificity.
This kit is a complete autochthonous creation by the R&D scientists working at the firm. They said that the most significant advantage of this kit is that it is easy to use and easily accessible simple reagents and primers, which can be synthesized in India.
They further added that the diagnosis takes approximately 2 hours.
Discrete research by Reliance Life Sciences has shown that the death rate from Covid-19 may remarkably diminish by the end of 2020. The research revealed that the mutation of the structural and non-structural proteins of SARS-CoV-2 form over 7,000 genome sequences of SARS-CoV-2 virus from 49 countries.
As per the study issued in the Scientific Journal of Biology, the statistical analysis presented a negative correlation between the mutation rates of two proteins NSP6 and Surface glycoprotein (S) with the death rate. It has also been prognosticated that these two proteins’ mutations will grow continually, while the death rate would sink below 0.5% by the year-end of 2020 in cluster I countries (India and Bangladesh).
In the study, it has been observed that the cluster II country (USA) mutation rate of NSP6 and S proteins are lower than cluster I and cluster III (Australia and New Zealand) countries. The study proffered that in cluster II countries, the death rate from Covid-19 will decline later than cluster I and III states.
Reliance also got a U.S. patent for genetically modified microalgae to reduce fatality in coronavirus cases.
The United States Patent and Trademark Office issued the patent on September 8.
